Skip to content
Home/Companies/Biotech/Roslinct
Roslinct

Roslinct

Biotech·United Kingdom·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Roslinct?

Roslinct is a British Biotech company, currently owned by GHO Capital since 2021.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
GHO Capital
Investor
GHO Capital
GHO Capital III LP · 2021 · Buyout

Key facts

HQUnited Kingdom
SectorBiotech
Websitewww.roslinct.com

More from GHO Capital III LP

Other portfolio companies in the same fund.

Alcami Corporation
Alcami Corporation
Active
PharmaUS· 2022
Sanner
Sanner
Active
MedTechGermany· 2022
Sapio Sciences
Sapio Sciences
Active
HealthTechUS· 2022
Biocare Medical
Biocare Medical
Exited 2026
MedTechUS· 2021
to Agilent Technologies
Clearview Healthcare Partners
Clearview Healthcare Partners
Active
Business ServicesUS· 2021
Envision Pharma
Active
HealthcareUK· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Roslinct?

Roslinct is currently owned by GHO Capital, through GHO Capital III LP, since 2021.

When did GHO Capital acquire Roslinct?

GHO Capital acquired Roslinct in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue